Advanced

Beneficial effects of aminoguanidine on the cardiovascular system of diabetic rats

Stadler, Krisztian ; Jenei, Veronica LU ; Somogyi, Aniko and Jakus, Judit (2005) In Diabetes/Metabolism Research & Reviews 21(2). p.189-196
Abstract
BACKGROUND: The study focused on investigating the effect of aminoguanidine on cardiovascular damages in diabetes and the possible mechanisms of its action. METHODS: Aminoguanidine (AMNG) was used to treat streptozotocin-induced diabetic rats, and the effects were compared to those obtained under insulin treatment. Blood metabolic parameters, *NO and ONOO- as well as protein carbonyl levels and cardiac hypertrophy were determined. RESULTS: Diabetic animals showed increased *NO levels and markedly increased ONOO- generation in the aorta, along with a significant hypertrophy and protein carbonylation in the cardiac tissue. Both AMNG and insulin treatment suppressed the levels of overproduced *NO or ONOO- in the vasculature, but only AMNG was... (More)
BACKGROUND: The study focused on investigating the effect of aminoguanidine on cardiovascular damages in diabetes and the possible mechanisms of its action. METHODS: Aminoguanidine (AMNG) was used to treat streptozotocin-induced diabetic rats, and the effects were compared to those obtained under insulin treatment. Blood metabolic parameters, *NO and ONOO- as well as protein carbonyl levels and cardiac hypertrophy were determined. RESULTS: Diabetic animals showed increased *NO levels and markedly increased ONOO- generation in the aorta, along with a significant hypertrophy and protein carbonylation in the cardiac tissue. Both AMNG and insulin treatment suppressed the levels of overproduced *NO or ONOO- in the vasculature, but only AMNG was able to prevent hypertrophic alterations and reduce protein carbonylation in the cardiac tissue. CONCLUSIONS: Oxidative protein modification, together with cardiac hypertrophy and high generation of *NO and ONOO-, are important early events in the development of cardiovascular complications in diabetes. Aminoguanidine could prevent hypertrophy through inhibition of production of nonenzymatic glycation products rather than via inhibition of *NO production. (Less)
Please use this url to cite or link to this publication:
author
; ; and
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
aminoguanidine, insulin, nitric oxide, diabetes, cardiac hypertrophy, EPR spectroscopy
in
Diabetes/Metabolism Research & Reviews
volume
21
issue
2
pages
189 - 196
publisher
John Wiley and Sons
external identifiers
  • pmid:15386808
  • scopus:16344393699
  • pmid:15386808
ISSN
1520-7552
DOI
10.1002/dmrr.501
language
English
LU publication?
yes
id
99b035a6-4d8b-431f-8594-571284eff144 (old id 1133171)
date added to LUP
2016-04-01 12:06:25
date last changed
2021-01-10 05:18:10
@article{99b035a6-4d8b-431f-8594-571284eff144,
  abstract     = {BACKGROUND: The study focused on investigating the effect of aminoguanidine on cardiovascular damages in diabetes and the possible mechanisms of its action. METHODS: Aminoguanidine (AMNG) was used to treat streptozotocin-induced diabetic rats, and the effects were compared to those obtained under insulin treatment. Blood metabolic parameters, *NO and ONOO- as well as protein carbonyl levels and cardiac hypertrophy were determined. RESULTS: Diabetic animals showed increased *NO levels and markedly increased ONOO- generation in the aorta, along with a significant hypertrophy and protein carbonylation in the cardiac tissue. Both AMNG and insulin treatment suppressed the levels of overproduced *NO or ONOO- in the vasculature, but only AMNG was able to prevent hypertrophic alterations and reduce protein carbonylation in the cardiac tissue. CONCLUSIONS: Oxidative protein modification, together with cardiac hypertrophy and high generation of *NO and ONOO-, are important early events in the development of cardiovascular complications in diabetes. Aminoguanidine could prevent hypertrophy through inhibition of production of nonenzymatic glycation products rather than via inhibition of *NO production.},
  author       = {Stadler, Krisztian and Jenei, Veronica and Somogyi, Aniko and Jakus, Judit},
  issn         = {1520-7552},
  language     = {eng},
  number       = {2},
  pages        = {189--196},
  publisher    = {John Wiley and Sons},
  series       = {Diabetes/Metabolism Research & Reviews},
  title        = {Beneficial effects of aminoguanidine on the cardiovascular system of diabetic rats},
  url          = {http://dx.doi.org/10.1002/dmrr.501},
  doi          = {10.1002/dmrr.501},
  volume       = {21},
  year         = {2005},
}